

Interview Summary	Application No. 10/005,212	Applicant(s) GILLIES ET AL.	
	Examiner Prema M Mertz	Art Unit 1646	

All participants (applicant, applicant's representative, PTO personnel):

(1) Prema M Mertz (Primary Examiner).

(3) Dr. J. Way.

(2) Brian Fairchild (Attorney).

(4) Dr. Stephen D. Gillies.

Date of Interview: 16 March 2004.

Type: a) ☐ Telephonic b) ☐ Video Conference

c) ☒ Personal [copy given to: 1) ☐ applicant 2) ☒ applicant's representative]

Exhibit shown or demonstration conducted: d) ☐ Yes e) ☒ No.

If Yes, brief description: _____.

Claim(s) discussed: 1-3,23 and 24.

Identification of prior art discussed: Trinchieri et al (US Patent No. 5,457,038) and WO 97/20062.

Agreement with respect to the claims f) ☐ was reached. g) ☐ was not reached. h) ☐ N/A.

Substance of Interview including description of the general nature of what was agreed to if an agreement was reached, or any other comments: See Continuation Sheet.

(A fuller description, if necessary, and a copy of the amendments which the examiner agreed would render the claims allowable, if available, must be attached. Also, where no copy of the amendments that would render the claims allowable is available, a summary thereof must be attached.)

THE FORMAL WRITTEN REPLY TO THE LAST OFFICE ACTION MUST INCLUDE THE SUBSTANCE OF THE INTERVIEW. (See MPEP Section 713.04). If a reply to the last Office action has already been filed, APPLICANT IS GIVEN ONE MONTH FROM THIS INTERVIEW DATE, OR THE MAILING DATE OF THIS INTERVIEW SUMMARY FORM, WHICHEVER IS LATER, TO FILE A STATEMENT OF THE SUBSTANCE OF THE INTERVIEW. See Summary of Record of Interview requirements on reverse side or on attached sheet.

Examiner Note: You must sign this form unless it is an Attachment to a signed Office action.

Prema Mertz
Examiner's signature, if required

Continuation of Substance of Interview including description of the general nature of what was agreed to if an agreement was reached, or any other comments: Applicant indicated that the p35 subunit of IL-12 had a tendency to be degraded rapidly in the absence of the p40 subunit. Furthermore, the heterodimeric fusion protein comprising a first chimeric chain comprising the p35 subunit of IL-12 and a portion of an IgG heavy chain and a second chain comprising the p40 subunit of IL-12 yielded an active secreted protein for which there was no clear expectation of success in the prior art .